Complete if Known 10/584.207 Application Number **INFORMATION DISCLOSURE** November 28, 2007 Filing Date STATEMENT BY APPLICANT Terence J. Colgan First Named Inventor 1649 (Use as many sheets as necessary) Art Unit Borgeest, C. M. Examiner Name MCY5USA 1 of 4 Attorney Docket Number Sheet **U.S. PATENT DOCUMENTS** Name of Patentee or Cite No.1 **Publication Date** Pages, Columns, Lines, Examiner Document Number MM-DD-YYYY Applicant of Cited Document Where Relevant Initials* Passages or Relevant Number-Kind Code2(if known) Figures Appear US-6,228,596 05-08-2001 Macina 1 2 US-2010-0172838 07-08-2010 Siu US-US-US-US-US-US-US-FOREIGN PATENT DOCUMENTS Publication Date Name of Patentee or Pages, Columns, Examiner Cite No.1 Foreign Patent Document Lines, Where Initials* MM-DD-YYYY Applicant of Cited T^6 Document Relevant Passages Country Code³- Number⁴-Kind Code⁵(if known) or Relevant Figures Appear 3 WO2008/049239 05-02-2008 Siu 4 WO2005/061725 07-07-2005 Colgan 5 WO2007/081767 07-19-2007 Moore 6 WO2002/009573 02-07-2002 Mutter Date Examiner /Christina Borgeest/ 9/30/2011

Signature

Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

orna alatanananana	Complete if Known									
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number 10/584,207						
				Filing Date		mber 28, 2007	2007			
SIAI	CIVIC	NIBYA	APPLICANI	First Named Inventor		ice J. Colgan	· · · · · · · · · · · · · · · · · · ·			
(Use as many sheets as necessary)				Art Unit	1649					
(000 10 mail, 5,1000 10 moccos 1,7)				Examiner Name	Borge	eest, C. M.				
Sheet	2 of 4			Attorney Docket Number MCY5USA						
			NON PATI	NT LITERATURE [OCUMEN	NTS				
Examiner Initials*	Cite No.1							T ²		
	7	SHAARAWY et al, Biomarkers of intrinsic and anti-angiogenic activity in patients								
		with endometrial hyperplasia and endometrial cancer, Acta Oncologica, 40(4):513-8 (January 2001)								
	8	DESMOND et al, Identification of genes differentially expressed in endometrial								
		carcinoma, Proceedings of the American Association for Cancer Research Annual								
			44:1198 (July 20							
	9	HARDT et al, Measurement of fecal pyruvate kinase type M2 (tumor M2-PK)								
		concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas								
		and controls, Database Biosis Accession No. PREV200300402239, Anticancer								
	10	Research, 23(2a):851-4 (March 2003) DESOUZA et al, Search for cancer markers from endometrial tissues using								
	10									
		differentially labeled tags iTRAQ and clCAT with multidimensional liquid								
		chromatography and tandem mass spectrometry, Journal of Proteome Research, 4(2):377-86 (March 2005)								
	11	DRAPKIN R., et al, Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein								
	11	that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas, Cancer								
		Research, Vol. 65, No. 6, pages 2162-2169 March 15, 2005								
	12	LI H et al, Identification of Candidate Biomarker Proteins Released by Human								
		Endometrial and Cervical Cancer Cells Using Two-Dimensional Liquid								
	Chromatography/Tandem Mass Spectrometry, Journal of Proteome Research, Vol. 6,									
	No. 7, pages 2615-2622, May 25, 2007									
	13									
		Carcinogenesis, Cancer Research, Vol. 60, pages 5007-5011, September 15, 2000								
	14	HELLSTROM et al, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma,								
p		Cancer Research, 63(13):3695-3700 (July 2003)								
	15 ACE, "Microarray profiling of progesterone-regulated endometrial genes during the									
	rhesus monkey secretory phase", Reproductive Biology and Endocrinology, 2:54-62,									
		July 2004	4							
Examiner		(Olester)	on Davagost/			Date	T			
Signature	/Christina Borgeest/					Considered	9/30/20)11		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $^{^{\}rm 1}$ Applicant's unique citation designation number (optional). $^{\rm 2}$ Applicant is to place a check mark here if English language Translation is attached.

Receipt date: 07/12/2011

					Complete if Knowl	7					
INFORMATION DISCLOSURE			TSCLOSURE	Application Number 10/584,207							
STATEMENT BY APPLICANT				Filing Date	November 28, 2007						
SIAI	CIVIE	MIDIA	APPLICANT	First Named Inventor	Terence J. Colgan						
(U	se as m	any sheets a	s necessary)	Art Unit	1649						
•		•	••	Examiner Name	Borgeest, C. M.	. M.					
Sheet	3	of	4	Attorney Docket Number	MCY5USA						
			l								
			NON PAT	ENT LITERATURE	OCUMENTS						
Examiner Initials*	Cite No.1										
	16										
		endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin									
		detection methods", Electrophoresis, 28(12):1989-1996, June 2007									
	17										
		implications for differential diagnosis", Modern Pathology, 19(8):1091-1100, Epub									
		April 28, 2006, August 2006									
	18	FERGUSON, "Stratification of intermediate-risk endometrial cancer patients into									
		groups at high risk or low risk for recurrence based on tumor gene expression profiles",									
		Clinical Cancer Research, 11(6):2252-2257, March 15, 2005									
	19	HEBBAR, "Differential expression of MUC genes in endometrial and cervical tissues									
		and tumors", BMC Cancer. 5:124-135, September 27, 2005									
	20	LI, "Is th	e measurement of	placental protein-14	and CA-125 in plasma	and uterine					
		flushings useful in the evaluation of peri-menopausal and post-menopausal bleeding?",									
		Human Reproduction, 13(10):2895-2901, October 1998									
	21	endomet	rium: protein iden	tification and differe	ative and secretory phas ntial protein expression'						
		5(1):270-281, January 2005									
	22	MUTTER, "Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation", Gynecologic Oncology 83(2):177-185, November 2001									
	23	B LALITKUMAR, "Placental protein 14 in endometrium during menstrual cycle and									
		effect of early luteal phase mifepristone administration on its expression in									
		implantation stage endometrium in the rhesus monkey", Human Reproduction,									
		13(12):3478-3486, December 1998									
	24										
	human tissues", Modern Pathology, 19(6):847-853, June 2006: E-pub April 7, 2006										
	25	ZIERAU	, "Tamoxifen exe	rts agonistic effects of	on clusterin and compler	nent C3 gene					
		expression in RUCA-I primary xenografts and metastases but not normal uterus",									
	Endocrine-Related Cancer, 11(4):823-830, December 2004										
Examiner		/Christina	Borgeest/		Date Considered	9/30/201	1 1				

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $^{^{\}rm 1}$ Applicant's unique citation designation number (optional). $^{\rm 2}$ Applicant is to place a check mark here if English language Translation is attached.

				Complete if Known				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number 10/584,207				
				Filing Date November 28, 2007				
JIA	E Box E E Sec. 1		AI I LIOAITI	First Named Inventor Terence J. Colgan Art Unit 1649				
(Use as ma	any sheets	as necessary)					
				Examiner Name	Borgeest, C. M.			
Sheet	4	of	4	Attorney Docket Number	MCY5USA			
	100							
	ОТ	HER IN		MITTED FOR CON 37 CFR §1.98(a)(SIDERATION BY THE OFFICE 1))			
Examiner Initials*	Cite No.1	For unpublished applications, include the name of the inventor (in CAPITAL LETTERS), US serial number, and filing date.						
	26	Extended European Search Report issued with Communication dated May 25, 2011 in related EP application No. 10169645.8						
	27	International Search Report dated May 11, 2005 issued in corresponding International application no. PCT/CA2004/002172						
	28	International Preliminary Report on Patentability dated June 26, 2006 issued in corresponding International application no. PCT/CA2004/002172						
	29	European Search Report dated April 7, 2008 issued in corresponding EP application No. 04802347.7						
	30	Communication dated September 9, 2008 issued in corresponding EP application No. 04802347.7						
	31	Applicant's response to communication dated September 9, 2008 filed on June 29, 2009 in corresponding EP application No. 04802347.7						
	32	International Preliminary Report on Patentability dated April 28, 2009 issued in related International application no. PCT/CA2007/001935						
	33	International Search Report dated February 22, 2008 issued in related International application no. PCT/CA2007/001935						
	34	Supplemental European Search Report dated September 15, 2010 issued in related EP application no. 07816085.0						
Examiner Signature		/Christ	ina Borgeest/		Date Considered			

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $^{^{\}rm 1}$ Applicant's unique citation designation number (optional). $^{\rm 2}$ Applicant is to place a check mark here if English language Translation is attached.